IP Library Granted Patent US 7,807,799
Granted Patent B2
US 7,807,799 · App. 12/269,752 · Granted Oct 5, 2010

Reducing protein A leaching during protein A affinity chromatography

Assignee: Genentech, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,807,799
App. No.
12/269,752
Granted
Oct 5, 2010
Kind
B2
Abstract

A method for reducing leaching of protein A during protein A affinity chromatography is described which involves reducing temperature or pH of, or by adding one or more protease inhibitors to, a composition that is subjected to protein A affinity chromatography.

Claims (15)

1. A method of purifying a protein which comprises a C H 2/C H 3 region, comprising subjecting a composition comprising said protein to protein A affinity chromatography at a temperature in the range from about 10 ° C. to about 18 ° C.

2. The method of claim 1 further comprising exposing the composition subjected to protein A affinity chromatography to a protease inhibitor.

3. The method of claim 2 wherein the protease inhibitor is EDTA or 4-(2-aminoethyl)-benzenesulfonyl-fluoride, hydrochloride (AEBSF).

4. The method of claim 2 comprising adjusting the pH of the composition prior to protein A affinity chromatography to a pH in the range from about 2.5 to about 3.5.

5. The method of claim 1 wherein the protein is an antibody.

6. The method of claim 5 wherein the antibody binds an antigen selected from the group consisting of HER2, vascular endothelial growth factor (VEGF), IgE, CD20, CD40, CD11a, tissue factor (TF), prostate stem cell antigen (PSCA), interleukin-8(IL-8), epidermal growth factor receptor (EGFR), HER3, HER4, α4β7 and α5β3.

7. The method of claim 5 wherein the antibody is selected from the group consisting of Trastuzumab, humanized 2C4, humanized CD11a antibody, and humanized VEGF antibody.

8. The method of claim 5 wherein the antibody binds HER2antigen.

9. The method of claim 8 wherein the antibody is Trastuzumab or humanized 2C4.

10. The method of claim 1 wherein the protein is an immunoadhesin.

11. The method of claim 10 wherein the immunoadhesin is a TNF receptor immunoadhesin.

12. A method of purifying a protein which comprises a C H 2/C H 3 region comprising:

a. subjecting a composition comprising said protein to protein A affinity chromatography to provide a recovered composition and measuring leached protein A in said recovered composition;

b. if greater than about 20 ng protein A per mg of said protein is measured in said recovered composition, then performing subsequent purification of compositions comprising said protein by protein A affinity chromatography at a temperature in the range from about 10° C. to about 18° C., such that protein A leaching is reduced; and

c. exposing the composition subjected to protein A affinity chromatography to a protease inhibitor in order to reduce the protease activity and further reduce leaching of protein A.

Continuity (3)
Continuation 1087753200 · Jun 24, 2004
Provisional Application 6049050000 · Jul 28, 2003
Related Publication 20090099344A1 · Apr 16, 2009